Cost-effectiveness of second-line ipilimumab for metastatic melanoma: a real-world population-based cohort study of resource utilization
Lu B, Dai WF, Croxford R, Isaranuwatchai W, Beca J, Menjak IB, Petrella TM, Mittmann N, Earle CC, Gavura S, Mercer RE, Hanna TP, Chan KKW. Cancer Med. 2023; 12(10):11451-61. Epub 2023 Mar 31.